JP2022526297A5 - - Google Patents

Info

Publication number
JP2022526297A5
JP2022526297A5 JP2021556467A JP2021556467A JP2022526297A5 JP 2022526297 A5 JP2022526297 A5 JP 2022526297A5 JP 2021556467 A JP2021556467 A JP 2021556467A JP 2021556467 A JP2021556467 A JP 2021556467A JP 2022526297 A5 JP2022526297 A5 JP 2022526297A5
Authority
JP
Japan
Prior art keywords
cell population
agglutination
tauri
repeat domain
reporter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021556467A
Other languages
English (en)
Japanese (ja)
Other versions
JP7389135B2 (ja
JP2022526297A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/023121 external-priority patent/WO2020190927A1/en
Publication of JP2022526297A publication Critical patent/JP2022526297A/ja
Publication of JP2022526297A5 publication Critical patent/JP2022526297A5/ja
Application granted granted Critical
Publication of JP7389135B2 publication Critical patent/JP7389135B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021556467A 2019-03-18 2020-03-17 タウ凝集に関連する遺伝的脆弱性を明らかにするためのcrispr/casドロップアウトスクリーニングプラットフォーム Active JP7389135B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962820101P 2019-03-18 2019-03-18
US62/820,101 2019-03-18
PCT/US2020/023121 WO2020190927A1 (en) 2019-03-18 2020-03-17 Crispr/cas dropout screening platform to reveal genetic vulnerabilities associated with tau aggregation

Publications (3)

Publication Number Publication Date
JP2022526297A JP2022526297A (ja) 2022-05-24
JP2022526297A5 true JP2022526297A5 (https=) 2023-09-27
JP7389135B2 JP7389135B2 (ja) 2023-11-29

Family

ID=70285886

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021556467A Active JP7389135B2 (ja) 2019-03-18 2020-03-17 タウ凝集に関連する遺伝的脆弱性を明らかにするためのcrispr/casドロップアウトスクリーニングプラットフォーム

Country Status (11)

Country Link
US (2) US11781131B2 (https=)
EP (1) EP3769090B1 (https=)
JP (1) JP7389135B2 (https=)
KR (1) KR102683424B1 (https=)
CN (1) CN113711046B (https=)
AU (1) AU2020241856B2 (https=)
CA (1) CA3127814C (https=)
ES (1) ES2969026T3 (https=)
IL (1) IL286359B2 (https=)
SG (1) SG11202108090XA (https=)
WO (1) WO2020190927A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3769090B1 (en) 2019-03-18 2023-11-15 Regeneron Pharmaceuticals, Inc. Crispr/cas dropout screening platform to reveal genetic vulnerabilities associated with tau aggregation
CN120648640A (zh) 2019-03-18 2025-09-16 瑞泽恩制药公司 用于鉴定tau接种或聚集的基因修饰因子的CRISPR/Cas筛选平台
CN113906134B (zh) 2019-06-14 2025-06-24 瑞泽恩制药公司 Tau蛋白病模型
CN114426982B (zh) * 2022-02-22 2024-03-22 上海交通大学 一种细胞代谢重编程的方法及其应用
WO2025217551A1 (en) * 2024-04-12 2025-10-16 University Of Miami Microrna-mediated obstruction of stem-loop alternative splicing

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001271553A1 (en) * 2000-06-23 2002-01-08 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
CN101333555B (zh) * 2007-12-25 2012-03-21 浙江大学 新型的g蛋白偶联受体细胞水平筛选系统构建与应用
JP2011517838A (ja) 2008-04-11 2011-06-16 ユーティーシー パワー コーポレイション マニホルド・サンプを備えたバイポーラプレートおよび燃料電池
US8586526B2 (en) 2010-05-17 2013-11-19 Sangamo Biosciences, Inc. DNA-binding proteins and uses thereof
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
SG10201708959WA (en) 2012-07-03 2017-11-29 Univ Washington Antibodies to tau
WO2014033644A2 (en) 2012-08-28 2014-03-06 Novartis Ag Methods of nuclease-based genetic engineering
AU2013335451C1 (en) 2012-10-23 2024-07-04 Toolgen Incorporated Composition for cleaving a target DNA comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof
US9910048B2 (en) 2012-12-03 2018-03-06 Washington University Method for detection of aggregates in biological samples
PL3360964T3 (pl) 2012-12-06 2020-03-31 Sigma-Aldrich Co. Llc Modyfikacja i regulacja genomu oparta na crispr
EP2840140B2 (en) 2012-12-12 2023-02-22 The Broad Institute, Inc. Crispr-Cas based method for mutation of prokaryotic cells
EP3031921B1 (en) 2012-12-12 2025-03-12 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
EP2931899A1 (en) 2012-12-12 2015-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
US20140186843A1 (en) 2012-12-12 2014-07-03 Massachusetts Institute Of Technology Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
DK2931891T3 (da) 2012-12-17 2019-08-19 Harvard College Rna-styret modificering af menneskelige genomer
EP2922393B2 (en) 2013-02-27 2022-12-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Gene editing in the oocyte by cas9 nucleases
CN112301024A (zh) 2013-03-15 2021-02-02 通用医疗公司 使用RNA引导的FokI核酸酶(RFN)提高RNA引导的基因组编辑的特异性
EP4286517A3 (en) 2013-04-04 2024-03-13 President and Fellows of Harvard College Therapeutic uses of genome editing with crispr/cas systems
US9267135B2 (en) 2013-06-04 2016-02-23 President And Fellows Of Harvard College RNA-guided transcriptional regulation
EP3725885A1 (en) 2013-06-17 2020-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
WO2015048577A2 (en) 2013-09-27 2015-04-02 Editas Medicine, Inc. Crispr-related methods and compositions
WO2015065964A1 (en) 2013-10-28 2015-05-07 The Broad Institute Inc. Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン,インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
US20150376586A1 (en) 2014-06-25 2015-12-31 Caribou Biosciences, Inc. RNA Modification to Engineer Cas9 Activity
CA2954791C (en) 2014-07-14 2025-11-18 The Regents Of The University Of California CRISPR/CAS TRANSCRIPTIONAL MODULATION
WO2016049258A2 (en) 2014-09-25 2016-03-31 The Broad Institute Inc. Functional screening with optimized functional crispr-cas systems
WO2016106236A1 (en) 2014-12-23 2016-06-30 The Broad Institute Inc. Rna-targeting system
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
US10676735B2 (en) 2015-07-22 2020-06-09 Duke University High-throughput screening of regulatory element function with epigenome editing technologies
AU2016365720B2 (en) 2015-12-07 2020-11-26 Arc Bio, Llc Methods and compositions for the making and using of guide nucleic acids
LT3436077T (lt) 2016-03-30 2025-06-25 Intellia Therapeutics, Inc. Lipidų nanodalelių vaisto formos, skirtos crispr/cas komponentams
WO2017172764A1 (en) 2016-04-01 2017-10-05 The Regents Of The University Of California Modified cell line and method of determining tauopathies
JP2019513415A (ja) * 2016-04-04 2019-05-30 イーティーエッチ チューリッヒ タンパク質産生及びライブラリー生成のための哺乳類細胞株
CN110267985B (zh) 2017-01-04 2023-05-23 H.隆德贝克有限公司 用于治疗眼科疾病的特异性针对过度磷酸化τ蛋白的抗体
GB201708998D0 (en) 2017-06-06 2017-07-19 Univ Leuven Kath Methods for identifying activators and suppressors
WO2019010384A1 (en) 2017-07-07 2019-01-10 The Broad Institute, Inc. METHODS FOR DESIGNING GUIDE SEQUENCES FOR GUIDED NUCLEASES
CN110891420B (zh) 2017-07-31 2022-06-03 瑞泽恩制药公司 Cas转基因小鼠胚胎干细胞和小鼠及其应用
KR20200033259A (ko) * 2017-07-31 2020-03-27 리제너론 파마슈티칼스 인코포레이티드 생체내에서 CRISPR/Cas-매개된 파괴 또는 삭제 및 외인성 도너 핵산과의 CRISPR/Cas-유도된 재조합을 평가하기 위한 방법 및 조성물
EP3592140A1 (en) 2018-03-19 2020-01-15 Regeneron Pharmaceuticals, Inc. Transcription modulation in animals using crispr/cas systems
CA3133983A1 (en) 2019-03-18 2020-09-24 Regeneron Pharmaceuticals, Inc. Methods and systems for crispr selection
CN120648640A (zh) 2019-03-18 2025-09-16 瑞泽恩制药公司 用于鉴定tau接种或聚集的基因修饰因子的CRISPR/Cas筛选平台
EP3769090B1 (en) 2019-03-18 2023-11-15 Regeneron Pharmaceuticals, Inc. Crispr/cas dropout screening platform to reveal genetic vulnerabilities associated with tau aggregation
CN113906134B (zh) 2019-06-14 2025-06-24 瑞泽恩制药公司 Tau蛋白病模型

Similar Documents

Publication Publication Date Title
JP2022526297A5 (https=)
JP7749631B2 (ja) Rna誘導性ヒトゲノム改変
AU2025203777A1 (en) CRISPR-Cas component systems, methods and compositions for sequence manipulation
CN107922944B (zh) 工程改造的crispr-cas9组合物和使用方法
US20200268907A1 (en) Compositions and methods for the expression of crispr guide rnas using the h1 promoter
JP2022127638A (ja) 最適化機能CRISPR-Cas系による配列操作のための系、方法および組成物
JP2023022254A (ja) Crispr/cpf1システム及び方法
JP2024071489A5 (https=)
CN116419975A (zh) 使用以位点特异性靶向元件实现的可编程添加(paste)来进行位点特异性遗传改造的系统、方法和组合物
US20180245075A1 (en) Integrated system for programmable dna methylation
US20190300867A1 (en) Bypassing the pam requirement of the crispr-cas system
US20180112255A1 (en) Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis
US20200123533A1 (en) High-throughput strategy for dissecting mammalian genetic interactions
Lemp et al. Cryptic transcripts from a ubiquitous plasmid origin of replication confound tests for cis-regulatory function
JP2020537646A5 (https=)
JP2022526099A5 (https=)
Chary et al. The absence of core piRNA biogenesis factors does not impact efficient transposon silencing in Drosophila
Spann et al. Mutagenesis and gene identification in Dictyostelium by shotgun antisense.
JP2007502129A (ja) 短鎖干渉rnaライブラリーならびに合成および使用の方法
EP0790304A1 (en) Improvements relating to assay systems
CN116875581A (zh) 利用Cpf1非滞留端提高基因敲进效率和精准度的方法
RU2021129022A (ru) Платформа crispr/cas для исключающего скрининга для выявления генетических уязвимостей, связанных с агрегацией тау-белка
Peled-Zehavi et al. [20] Screening RNA-binding libraries by transcriptional antitermination in bacteria
RU2024112968A (ru) Скрининговая платформа crispr/cas для идентификации генетических модификаторов засева или агрегации тау-белка
Ramakrishnan et al. A high-content flow cytometry and dual CRISPR-Cas9 based platform to quantify genetic interactions